Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q2 2025 (June 30)4holders −2
2new positions
4sold out
$0.05avg. 13F price*
At the end of Q2 2025, 4 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, down 2 from Q1 2025. 2 opened new positions and 4 sold out. The largest holders were Clear Street LLC ($5K), Susquehanna International Group, LLP ($1K) and Two Sigma Securities, LLC ($536).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $541 |
| Exits | 4 | $2K |
All 13F filers, Q1 2025 → Q2 2025: 11,342 shares bought and 243,467 shares sold, net −232,125 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Clear Street LLC | — | No change | 100,000 | $5K |
| Susquehanna International Group, LLP | — | Reduce -49.4% | 25,378 | $1K |
| Two Sigma Securities, LLC | — | New | 11,242 | $536 |
| Bank of America Corp. | — | New | 100 | $5 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.